Physician profile
Mark A Rasmus
NPI 1528106309
$43,522.96
in general payments reported to CMS, 2019-2025
18 companies · $7,222 in 2025
The $7,222 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,414 · 2020: $624 · 2021: $8,859 · 2022: $4,897 · 2023: $10K · 2024: $4,479 · 2025: $7,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,861 · Honoraria: $5,725 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,924 · Food and Beverage: $2,701 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,050 · Education: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,860.50 |
| Honoraria | $5,725.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,924.00 |
| Food and Beverage | $2,700.96 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,050.00 |
| Education | $468.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $16,443.03 | 2020-2025 | Wakix |
| Axsome Therapeutics, INC. | $12,729.18 | 2023-2025 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $6,967.23 | 2019-2021 | |
| Fisher & Paykel Healthcare INC | $2,330.30 | 2019-2024 | Fisher & Paykel Healthcare |
| Inspire Medical Systems, INC. | $1,783.03 | 2019-2023 | Inspire |
| Jazz Pharmaceuticals INC. | $1,737.26 | 2019-2025 | |
| Philips North America LLC | $464.96 | 2019-2023 | |
| Avadel Cns Pharmaceuticals, LLC | $378.27 | 2023-2025 | Lumryz |
| Eisai INC. | $164.96 | 2020-2021 | |
| Glaxosmithkline, LLC. | $131.01 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.95 | 2025 | |
| Arbor Pharmaceuticals, INC. | $94.32 | 2019-2022 | |
| 3b Medical, INC. | $36.90 | 2023-2025 | Luna |
| Vanda Pharmaceuticals INC. | $36.82 | 2022 | |
| Itamar Medical INC | $30.09 | 2024 | Watchpatone |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $29.51 | 2025 | Horizant |
| Resmed Corp | $29.15 | 2019 | |
| Viatris Specialty LLC | $16.99 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rasmus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.